Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 dichloride (Xofigo) and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).
The combination of radium-223 and VEGF-targeted agents is feasible and safe. There was no dose limiting toxicity with the combination. There is a particular interest in investigating hematologic toxicity because radium-223 can affect bone marrow, says Bosse.
The toxicity profile is reassuring and overlaps what is known with VEGF targeted therapy, states Bosse. There was only one event of grade 3 anemia, which was not unexpected in the RCC population.
